Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
| EAGLE BULK S | EGLE | 7.84% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Retractable syringes maker Unilife Corporation ( UNIS - Snapshot Report ) has successfully completed all the required validation tests for its Unifill ready-to-fill (prefilled) syringe, representing the final step in the industrialization process of this unique device.
The achievement underscores that the Unifill syringe is fully compliant with all major regulatory requirements and meets the company’s own standards for device quality, reliability and functionality.
Unilife began initial production of the Unifill syringe at its FDA-approved plant located in York, Pennsylvania, in late March 2011. The company is currently in the process of negotiating with more than 20 pharmaceutical companies who have shown interest in its syringe.
It is anticipated that these pharmaceutical makers will buy from the early production lots, in order to conduct their own formal appraisal of the Unifill syringe in combination with their injectable drugs or vaccines. The completion of the product verification and validation phase opens the way for the product to be shipped to these customers. Unilife plans to commence initial sales in the near future.
Prefilled syringes act as the main drug container for about 50 injectable vaccines and drugs that are marketed by over 20 pharmaceutical companies. Unilife is of the opinion that the pharma market for prefilled syringes is the fastest-growing, relatively uncongested and the most lucrative segment of the global syringes industry.
The first-of-its-kind Unifill syringe is expected to revolutionize the $2.7 billion devices market for prefilled syringes as it is way ahead of the currently available prefilled syringes.
Pennsylvania-based Unilife is a medical devices company that designs, manufactures and sells advanced drug delivery systems. It collaborates with biotech and pharmaceutical companies and explores new devices that could be used with their drugs.
The company has developed a wide array of its own injectable drug delivery products, including retractable syringes. It sells its prefilled syringes to pharmaceutical manufacturers, suppliers of medical products to healthcare facilities and patients who self-administer prescription drugs.
Unilife’s patented syringes provide integrated safety, which is designed to protect patients from needle stick injuries. The company competes with Becton, Dickinson and Company ( BDX - Analyst Report ) among others.
Read the full reports :
Snapshot Report on UNIS
Analyst Report on BDX